Avastin for CNV Secondary to Pattern Dystrophy
Recruitment status was: Recruiting
The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but it seems that visual function may be preserved only in the short-term follow-up, with progressive deterioration thereafter.
Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion, but unfortunately, this approach does not appear to guarantee long-term vision stabilization, and alternative therapies should be investigated.
Choroidal Neovascularization Secondary to Pattern Dystrophy
Procedure: intravitreal triamcinolone injection of avastin (1.25 mg)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy|
- number of eyes with <15 letter loss (approximately <3 lines) at 6-month examination compared with the baseline value
- numeber of eyes with <15 letter loss at 12-month examinations, compared with the baseline value.
- CNV progression
- number of injections.
|Study Start Date:||July 2006|
|Estimated Study Completion Date:||October 2006|
Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin (1.25 mg) in operating room under sterile condition.
Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00391144
|Contact: Maurizio B Parodi, MD||+39 040 email@example.com|
|Contact: Giuseppe Ravalico, MD||+39 040 firstname.lastname@example.org|
|Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste||Recruiting|
|Trieste, TS, Italy, 34129|
|Contact: Giuseppe Ravalico, MD +39 040 772449 email@example.com|
|Principal Investigator:||Maurizio B Parodi, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|
|Principal Investigator:||Pierluigi Iacono, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|
|Study Director:||Giuseppe Ravalico, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|